Antigenics Inc. (Lexington, MA) Struggles to Obtain Regulatory Approval for Oncophage
Masshightech.com -- Antigenics Inc. has spent between $400 million and $500 million to conduct two Phase 3 trials on its potential cancer vaccine. But the Lexington-based company never plans to send it to the U.S. Food and Drug Administration for approval.